EAGAN, MN / ACCESSWIRE / September 23, 2021 / Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2021, and provided an update on recent business highlights.
CEO Commentary
"Customer and dealer reaction to Dynatronics' optimization strategy confirmed the changes and decisions we made in April 2021, and our transformation remains the top priority," said John Krier, Chief Executive Officer of Dynatronics. "Customer and dealer demand forecasts have provided us the confidence to initiate revenue guidance. We anticipate good progress in FY '22, with revenues benefitting from our growing markets as we work to improve margins and build long-term value for our shareholders."
Key Financial Highlights
Q4 FY '21 Financial Highlights
Note: All financials referenced in this release are in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and comparisons in this release are to the same period in the prior year unless otherwise noted.
- Total net sales of $12.2 million and gross profit margin of 19.1% (GAAP results).
- Continued product net sales of $9.8 million (non-GAAP financial measure).
- Net income of $2.9 million compared to net loss of $2.3 million in the same quarter last year.
- Notable events in Q4 FY '21:
- Cost of sales and SG&A collectively impacted by $1.0 million in optimization activity costs.
- Other Income benefitted from the $3.5 million PPP loan forgiveness, $0.9 million Employee Retention Credit, and $0.8 million gain on sale of former Tennessee manufacturing facility.
- No debt, zero balance on the line of credit, and a borrowing base of approximately $5.0 million as of the end of Q4 FY '21.
- Cash of $6.1 million at the end of Q4 FY '21, the highest cash position in recent years.
Dynatronics defines continued product net sales as sales in Q4 FY ‘21 on products that the company plans to continue offering to customers in FY '22.
FY '21 Financial Highlights
Total net sales of $47.8 million and gross profit margin of 27.0% (GAAP results). Excluding $0.5 million optimization exit activity costs, fiscal year '21 gross profit margin on total net sales would have been 28.0% (non-GAAP financial measure).
Guidance for FY '22
Customer and dealer demand forecasts have provided the company with the confidence to initiate net sales guidance for FY ‘22.
Product sales in FY '22 will represent products the company plans to offer moving forward since the optimization initiatives announced on April 22, 2021 were substantially completed in FY '21. Net sales are on pace to achieve approximately $11.5 to $12.0 million for Q1 FY '22, which exceeds the ˜$9.25 million quarterly continued product net sales baseline set in April 2021 and the $9.8 million continued product net sales in Q4 FY '21. Dynatronics expects, assuming continued growth in procedure volume despite the recent surge in COVID-19, net sales in FY '22 to be $40 million to $45 million. The mid-point of this range is a 15% improvement relative to the ˜$37 million annual continued product net sales baseline set in April 2021. The company expects the distribution of net sales across the quarters in FY '22 to align with historical trends, which have tended to be a little higher in the first and fourth quarters and lower in the second and third quarters. There may be some variability in this pattern, as the company is adjusting to ordering patterns in its rehabilitation market given the transition to an exclusive dealer-based sales model.
The company is targeting improvement over time in gross margin, operating income, and cash flow from operations. Absent significant impacts from COVID-19 outbreaks, the company expects those financial metrics will improve in FY '22 relative to FY '21, excluding the notable Other Income events experienced in Q4 FY ‘21.
Selling, General, and Administrative expenses are anticipated to be 30% to 35% of net sales in Q1 FY '22. Other income is expected to include an approximately $0.6 million benefit from the Employee Retention Credit in Q1 FY '22.
The company's financial guidance for FY '22 is subject to the risks identified in our Safe Harbor Notification below. The company and its customers expect to experience continued challenges due to COVID-19, including higher delivery and shipment costs, supply chain disruptions, and extended handling times. Dynatronics also expects some continued volatility from the company's business optimization.
Growth Priorities
While each of the following strategies is very important to Dynatronics' growth platform, the first four items are our focus in the first half of FY '22, as we see near-term opportunities:
- Deliver commercial success, emphasizing quality for cost and a differentiated customer experience
- Improve margins through consolidations and financial discipline
- Continue focus on cash flow from operations
- Timely commercial launch of new products focused on growth markets
- Optimize manufacturing and supply chain
- Rationalize product portfolio and pricing for attractive growth trends
- Target acquisitions in existing or adjacent markets with customer uptake
Conference Call and Webcast
The company will hold a conference call and live audio webcast to discuss the results, consisting of prepared remarks by management, slide presentation, and a question-and-answer session with analysts, beginning at 8:30 AM ET on Thursday, September 23, 2021.
Interested persons may access the live conference call by dialing 844-407-9500 (U.S./Canada callers) or 862-298-0850 (international callers). It is recommended that participants call or login 10 minutes ahead of the scheduled start time to ensure proper connection. An audio replay will be available one hour after the live call until Midnight on September 30, 2021, by dialing 877-481-4010, using passcode 42721.
The live webcast and slide presentation can be accessed on the company's Investor webpage under the Events & Presentations tab at https://irdirect.net/DYNT/corporate_document/1982. The webcast will be archived on the website for future viewing.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann™, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Those statements include references to the company's expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our statements regarding expected improvement in overall performance, expectations that the company will deliver higher annual gross margins, operating income and cash flow from operations in fiscal year 2022 compared to fiscal year 2021, expectations regarding reduction in leased space in fiscal year 2022, expectations regarding net sales, gross margin, selling general and administrative costs, and other income in fiscal year 2022, and uncertainties involving the impact of the COVID-19 pandemic on the company's results of operations and financial condition.
About Non-GAAP Financial Measures
Continued product net sales and gross profit margin excluding exit activity costs as used in this press release are non-GAAP measures as defined under the rules of the Securities and Exchange Commission. The company defines continued product net sales as sales excluding discontinued products and sales of physical therapy and rehabilitation products through our direct sales channel. Management uses these non-GAAP measures to evaluate our operating performance and to forecasting future periods. Management believes these non-GAAP measures provide investors additional information about the company's ongoing operating performance and is not intended as a substitute for, or superior to, the financial measures prepared in accordance with GAAP. Investors are cautioned against placing undue reliance on these non-GAAP measures.
Summary Financial Results
Following is a summary of operating results for the periods ended June 30, 2021 and 2020, the balance sheet highlights at June 30, 2021 and June 30, 2020 and cash flow for periods ended June 30, 2021 and 2020.
| Summary Selected Financial Data | ||||||||||||||||
| Statement of Operation Highlights | ||||||||||||||||
| In thousands, except share and per share amounts | ||||||||||||||||
| Quarter Ended | Year Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net sales | $ | 12,238 | $ | 8,116 | $ | 47,799 | $ | 53,409 | ||||||||
| Cost of sales | 9,900 | 6,703 | 34,913 | 38,311 | ||||||||||||
Gross profit | 2,338 | 1,413 | 12,886 | 15,098 | ||||||||||||
| 19.1% | 17.4% | 27.0% | 28.3% | |||||||||||||
| Selling, general, and admin. expenses | 4,558 | 3,641 | 16,646 | 18,091 | ||||||||||||
| Other (expense) income, net | 5,134 | (78 | ) | 5,752 | (442 | ) | ||||||||||
| Income tax provision | 20 | 10 | 10 | 10 | ||||||||||||
Net income (loss) | $ | 2,934 | $ | (2,296 | ) | $ | 2,002 | $ | (3,425 | ) | ||||||
Deemed dividend on convertible preferred stock and accretion of discount | - | - | (51 | ) | (174 | ) | ||||||||||
Convertible preferred stock dividend, in common stock | (182 | ) | (180 | ) | (741 | ) | (718 | ) | ||||||||
Net income (loss) attributable to common stockholders | $ | 2,752 | $ | (2,476 | ) | $ | 1,210 | $ | (4,317 | ) | ||||||
Net loss attributable to common stockholders per common share - basic and diluted | $ | 0.16 | $ | (0.18 | ) | $ | 0.08 | $ | (0.42 | ) | ||||||
Weighted-average common shares outstanding - basic and diluted | 17,557,595 | 13,461,148 | 15,461,339 | 10,262,769 | ||||||||||||
| Balance Sheet Highlights | ||||||
| In thousands | ||||||
| June 30, 2021 | June 30, 2020 | |||||
Cash and cash equivalents | $ | 6,254 | $ | 2,316 | ||
Trade accounts receivable, net | 5,643 | 4,894 | ||||
Inventories, net | 6,526 | 8,372 | ||||
Prepaid & other | 2,483 | 493 | ||||
Total current assets | 20,906 | 16,075 | ||||
Non-current assets | 18,234 | 21,522 | ||||
Total assets | $ | 39,140 | $ | 37,597 | ||
Accounts payable | $ | 3,738 | $ | 3,014 | ||
Accrued payroll and benefits expense | 1,656 | 1,205 | ||||
Accrued expenses | 1,485 | 768 | ||||
Other current liabilities | 1,593 | 1,679 | ||||
Line of credit | - | 1,013 | ||||
Total current liabilities | 8,472 | 7,679 | ||||
Non-current liabilities | 5,154 | 10,022 | ||||
Total liabilities | 13,626 | 17,701 | ||||
Stockholders' equity | 25,514 | 19,896 | ||||
Total liabilities and stockholders' equity | $ | 39,140 | $ | 37,597 | ||
| Cash Flow Highlights | ||||||||||||||||
| In thousands | ||||||||||||||||
| Quarter Ended | Year Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
Net income (loss) | $ | 2,934 | $ | (2,295 | ) | $ | 2,001 | $ | (3,425 | ) | ||||||
Depreciation and amortization | 368 | 397 | 1,480 | 1,618 | ||||||||||||
Stock based compensation | 26 | 45 | 154 | 279 | ||||||||||||
Gain on extinguishment of debt | (3,518 | ) | - | (3,518 | ) | - | ||||||||||
(Gain) loss on sale of property and equipment | (745 | ) | 19 | (717 | ) | 38 | ||||||||||
Receivables | 160 | 1,739 | (749 | ) | 2,601 | |||||||||||
Inventory | 403 | 2,951 | 551 | 3,156 | ||||||||||||
Prepaid and other assets | 313 | 445 | (741 | ) | 195 | |||||||||||
Accounts payable, accrued expenses, and other liabilities | 128 | (2,758 | ) | 1,922 | (1,371 | ) | ||||||||||
Net cash provided by operating activities | 69 | 543 | 383 | 3,091 | ||||||||||||
Net cash used in investing activities | 1,620 | (43 | ) | 1,532 | (291 | ) | ||||||||||
Payments on non-current liabilities | (86 | ) | (1,998 | ) | (1,439 | ) | (3,024 | ) | ||||||||
Proceeds from issuance of common stock, net | - | 2,287 | 3,462 | 2,287 | ||||||||||||
Net cash provided by (used in) financing activities | (86 | ) | 289 | 2,023 | (737 | ) | ||||||||||
Net change in cash and cash equivalents | 1,603 | 789 | 3,938 | 2,063 | ||||||||||||
Cash and cash equivalents at beginning of the period | 4,651 | 1,530 | 2,316 | 256 | ||||||||||||
Cash and cash equivalents at end of the period | $ | 6,254 | $ | 2,319 | $ | 6,254 | $ | 2,319 | ||||||||
Contact:
Dynatronics Corporation
Investor Relations
Skyler Black
(801) 676-7201
[email protected]
Darrow Associates
Jeff Christensen, Managing Director
(703) 297-6917
[email protected]
For additional information, please visit: www.dynatronics.com
Connect with Dynatronics on LinkedIn
SOURCE: Dynatronics Corporation